Company news

PTC Therapeutics, Inc. news in 2024

PTC Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 22, 2024

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

December 18, 2024

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

December 1, 2024

PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million

November 26, 2024

PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients

November 25, 2024

PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy

November 12, 2024

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 6, 2024

PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission

October 29, 2024

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results

October 23, 2024

CHMP Maintains Negative Opinion on Translarna™ Reexamination

October 17, 2024

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

October 13, 2024

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

October 7, 2024

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

September 30, 2024

FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program

September 25, 2024

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 7, 2024

PTC Therapeutics Announces Sepiapterin NDA Submission to FDA

July 29, 2024

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results

July 24, 2024

CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review

June 27, 2024

Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients

June 19, 2024

PTC Therapeutics to Participate at Upcoming Investor Conference

May 28, 2024

PTC Therapeutics Announces Validation of Sepiapterin European MAA

May 27, 2024

PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

May 19, 2024

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™

May 13, 2024

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

April 24, 2024

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

April 10, 2024

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

March 27, 2024

PTC Therapeutics Provides Key Regulatory Updates

March 18, 2024

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

February 14, 2024

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure

January 24, 2024

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024